3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Colorectal Cancer Metastatic
1
Carcinoma, Hepatocellular
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Bevacizumab
17
Capecitabine
13
Cetuximab
10
Oxaliplatin
8
Irinotecan
8
Fluorouracil
7
Panitumumab
5
Leucovorin
4
trifluridine tipiracil drug combination
3
sintilimab
3
regorafenib
3
Nivolumab
3
Ipilimumab
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Folfox protocol
2
Drug Therapy
2
spartalizumab
1
pembrolizumab
1
irinotecan sucrosofate
1
glucopyranosyl lipid-A
1
folfirinox
1
camrelizumab
1
balstilimab
1
anisodamine
1
aflibercept
1
XELOX
1
Vemurafenib
1
Tyrosine Kinase Inhibitors
1
Transurethral Resection of Prostate
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Colorectal Cancer Metastatic
×
Antineoplastic Agents
×
Clear all
NCT03923036
2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
2,000 enrolled